Severe community-acquired pneumonia: What's in a name?

Current Opinion in Infectious Diseases

Volumn 16, Issue 2, 2003, Pages 153-159

  Oosterheert, Jan Jelrik ^a   Bonten, Marc J M ^a,b   Hak, Eelko ^a   Schneider, Margriet M E ^a   Hoepelman, Andy I M ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Definition; Etiology; Severe community acquired pneumonia; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; INFLUENZA VACCINE; MACROLIDE; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; HEREDITY; HIGH RISK POPULATION; HUMAN; INFLUENZA VACCINATION; INTENSIVE CARE UNIT; LEGIONELLA PNEUMOPHILA; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0037399060     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200304000-00012     Document Type: Review

References (63)

1. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10:1530-1534.
2. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161:722-727. This is a good overview of available studies evaluating switch-therapy in community-acquired pneumonia.
3. Moine P, Vercken JB, Chevret S, et al. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994; 105:1487-1495.
4. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312-318.
5. Baudouin SV. The pulmonary physician in critical care. 3: critical care management of community acquired pneumonia. Thorax 2002; 57:267-271.
6. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (suppl 4):IV1-64. This provides a complete overview and discussion on current management options for patients with CAP.
7. American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia. Am J Crit Care Med 2001; 163:1730-1754. This is another complete overview and discussion on current management options for patients with CAP.
8. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect. Dis 2000; 31:347-382.
9. Neuhaus T, Ewig S. Defining severe community-acquired pneumonia. Med Clin North Am 2001; 85:1413-1425. The authors tried to define SCAP based on a pathophysiological approach and clinical outcomes.
10. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997; 336:243-250.
11. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158:1102-1108.
12. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-723. The authors revealed that two important diagnostic guidelines for SCAP have their limitations in predicting adverse outcomes.
13. El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163:645-651. This is a good overview of the etiology of SCAP.
14. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39:3495-3498.
15. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002; 121:1485-1492. This prospective evaluation shows the limitations in the diagnostic value of sputum gram stain and its impact on treatment decisions.
16. Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol 2002; 40:3232-3236.
17. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923-929.
18. Vegelin AL, Bissumbhar P, Joore JCA, et al. Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 1999; 55:110-117.
19. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community acquired pneumonia: impact of age, comorbidity and severity. Am J Resp Crit Care Med 1999; 160:397-405.
20. Rello J, Catalan M, Diaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28:1030-1035. In this retrospective study, illness-severity was associated with antimicrobial treatment, for example, the use of macrolides was associated with less severe disease.
21. Chen MZ, Hsueh PR, Lee LN, et al. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120:1072-1077.
22. Lim WS, Macfarlane JT, Boswell TCJ, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:295-301. This is a good overview of the etiology of SCAP.
23. Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001; 184:268-277. This was a prospective study evaluating the etiologies of patients with SCAP and non-severe CAP, in patients both with and without HIV infection.
24. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51:179-184.
25. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118:1344-1354.
26. Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A. Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Curr Opin Infect Dis 2001; 14:703-709. This provides a good overview of current opinions in SCAP.
27. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-141.
28. Leroy O, Devos P, Guery B, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest 1999; 116:157-165.
29. Riquelme R, Torres A, El Ebiary M, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154:1450-1455.
30. Roy S, Knox K, Segal S, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359:1569-1573. This article shows that genetic factors may play an important role in pathophysiology of CAP.
31. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163:1599-1604. This was a prospective study evaluating the risk of developing septic shock in CAP-patients with tumor necrosis factor-α gene polymorphisms.
32. Woodhead MA, Macfarlane JT. American Thoracic Society: Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 1987; 81:133-139.
33. Farr BM, Kaiser DL, Harrison BDW, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989; 44:1031-1035.
34. Macfarlane JT, Miller AC, Roderick Smith WH, et al. Comparative radiographic features of community-acquired legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984; 39:28-33.
35. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med 2002; 162:682-688. The authors evaluated quality of care variables and their impact on length of hospital stay.
36. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080-2084.
37. Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002; 28:686-691. In this article, the authors evaluate prognostic factors for patients with Legionella pneumophila infection.
38. Kasteren MEE van, Wijnands WJ, Stobbering EE, et al. Optimizing of antibiotic policy in the Netherlands. II, SWAB guidelines for the antimicrobial therapy of pneumonia in patients at home and as nosocomial infections. The Netherlands Antibiotics Policy Foundation [in Dutch]. Ned Tijdschr Geneeskd 1998; 142:952-956.
39. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842. This article raises the important question whether combination therapy in pneumococcal pneumonia is associated with better outcomes than monotherapy.
40. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-2572.
41. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pnuemonia. Arch. Intern. Med 1999; 159:2576-2580.
42. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states. Chest 2001; 119:1420-1426. This study investigated the impact of empiric antibiotic therapy on outcomes of patients with CAP.
43. Mufson MA, Stanek RJ. Bacteriemic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107:34S-43S.
44. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446-452.
45. Macfarlane J. Severe pneumonia and a second antibiotic. Lancet 2002; 359:1170-1172. This editorial adds several important notes to the study of Waterer et al. [39••]
46. The best treatment for pneumonia. New clues but no definitive answers. Arch Intern Med 1999; 159:2511-2512.
47. Guthrie R. Community-acquired lower respiratory tract infections, etiology and treatment. Chest 2001; 120:2021-2034. This article presents an overview of the newer fluoroquinolones.
48. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-1754.
49. Davidson R, Cavalcanti R, Brunton J, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-749. This presents four case reports illustrating resistance mechanisms of S. pneumoniae to fluoroquinolones.
50. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2:404-415. This provides a good overview of strategies to treat drug-resistant pneumococcal pneumonia.
51. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333-1339.
52. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399-403.
53. Hak E, Hoes A, Verheij TJ. Influenza vaccination. Who needs them and When? Drugs 2002; 62:2413-2420.
54. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002; 34:1613-1620. This is an overview of mechanisms of antimicrobial resistance in S. pneumoniae and its implications for management.
55. Gross PA. Vaccines for pneumonia and new antiviral therapies. Med Clin North Am 2001; 85:1531-1544.
56. Hak E, Grobbee DE, van Essen GA, et al. Pneumococcal vaccination of the elderly: do we need another trial? Arch Intern Med 2000; 160:1698-1699.
57. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-2442.
58. Christenson B, Lundbergh P, Hedlund J, Ortqvist A: Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357:1008-1011. This prospective study evaluated the use of influenza vaccination in a large and elderly population.
59. Ahmed F, Singleton JA, Franks AL. Clinical practice. Influenza vaccination for healthy young adults. N Engl J Med 2001; 345:1543-1547. The authors discuss the question of whether the use of influenza vaccination for healthy young adults is beneficial.
60. Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. (editorial) Clin Infect Dis 2001; 33:2078-279.
61. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clinical Infectious Diseases 2001; 31:444-450. Both costs and effects of pneumococcal vaccination were evaluated in this analysis.
62. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123:518-527.
63. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18:957-1030.